Epidermal Growth Factor Receptor as a Model Drug Target for Scrutinizing the Status Quo in Drug Discovery and Chemical Biology

High Resolution Image Download MS PowerPoint Slide Drug discovery scientists and chemical biologists continually seek to improve strategies for compound development. Here, we present insights derived from multiple studies of the epidermal growth factor receptor (EGFR), illustrating how this well-established target can inform practical aspects of drug discovery. Case studies spanning fragment-based drug design, bivalent inhibitor discovery, and the optimization of irreversible covalent inhibitors demonstrate how focused investigation of a single system can serve as a framework for methodological innovation and generation of broadly applicable knowledge. We propose that these collective efforts exemplify an emerging paradigm in medicinal chemistry, wherein “model drug targets” are deliberately leveraged to yield generalizable design principles and uncover new strategies for ligand discovery and chemical probe development.

Authors

Institutions

Publication Details

Journal
ACS Bio & Med Chem Au
Published
2026-06-17
DOI
https://doi.org/10.1021/acsbiomedchemau.6c00089
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Epidermal Growth Factor Receptor as a Model Drug Target for Scrutinizing the Status Quo in Drug Discovery and Chemical Biology

David E. Heppner, Monica R. MacDonald, Shilpa E. Naik, Sahba Cunningham et al.
ACS Bio & Med Chem Au
HER2/EGFR in Cancer Research
article

Epidermal Growth Factor Receptor as a Model Drug Target for Scrutinizing the Status Quo in Drug Discovery and Chemical Biology

David E. Heppner, Monica R. MacDonald, Shilpa E. Naik, Sahba Cunningham, Nader N. Nasief
article en

Abstract

High Resolution Image Download MS PowerPoint Slide Drug discovery scientists and chemical biologists continually seek to improve strategies for compound development. Here, we present insights derived from multiple studies of the epidermal growth factor receptor (EGFR), illustrating how this well-established target can inform practical aspects of drug discovery. Case studies spanning fragment-based drug design, bivalent inhibitor discovery, and the optimization of irreversible covalent inhibitors demonstrate how focused investigation of a single system can serve as a framework for methodological innovation and generation of broadly applicable knowledge. We propose that these collective efforts exemplify an emerging paradigm in medicinal chemistry, wherein “model drug targets” are deliberately leveraged to yield generalizable design principles and uncover new strategies for ligand discovery and chemical probe development.

ACS Bio & Med Chem Au
Roswell Park Comprehensive Cancer Center (US), National Organization for Drug Control and Research (EG), Egyptian Government (EG), Jacobs (United States) (US), University at Buffalo, State University of New York (US)
National Institute of General Medical Sciences
Openalex Percentile: Top 11%
HER2/EGFR in Cancer Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.